Advertisement

Topics

Safety Issues Not Dampening AbbVie Optimism For Humira Successors

19:33 EDT 2 Aug 2017 | SCRIP

AbbVie is optimistic that its JAK1 inhibitor upadacitinib and anti-IL23 candidate risankizumab can increase its autoimmune market share, doubting a...

      

Related Stories

 

Original Article: Safety Issues Not Dampening AbbVie Optimism For Humira Successors

NEXT ARTICLE

More From BioPortfolio on "Safety Issues Not Dampening AbbVie Optimism For Humira Successors"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...